Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218668 · ClinicalTrials.gov registry record · Phase 2
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Woolsey Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 12
- Study locations
NCT05218668 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is active but no longer recruiting, run by Woolsey Pharmaceuticals. The registered enrollment target is 40 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT05218668, a Phase 2 study of Amyotrophic Lateral Sclerosis, is active but no longer recruiting, sponsored by Woolsey Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Conditions Studied
Interventions
- DRUG Fasudil (WP-0512)
Study Locations (12)
Colorado
- University of Colorado - Aurora
- National Jewish Health - Denver
Florida
- Lakes Research - Miami Lakes
- University of South Florida - Tampa
Arizona
- Neuromuscular Research Center - Phoenix
Illinois
- Northwestern University - Chicago
Kentucky
- University of Kentucky - Lexington
Missouri
- Cox Medical Center - Springfield
New York
- Hospital for Special Surgery - New York
New South Wales
- Macquarie University Hospital - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05218668
The ClinicalTrials.gov registry entry for NCT05218668 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Woolsey Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fasudil (WP-0512) is the first listed.
NCT05218668 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Colorado, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05218668 about?
NCT05218668 is a clinical study titled "Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)". A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
What is the current status of trial NCT05218668?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-12-22. Estimated completion is 2029-01.
What conditions does trial NCT05218668 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05218668?
The interventions under investigation include: Fasudil (WP-0512) (DRUG).
Who is sponsoring clinical trial NCT05218668?
This trial is sponsored by Woolsey Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05218668 being conducted?
This trial has 12 study locations across Arizona, Colorado, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.